Humanized monoacylglycerol acyltransferase 2 mice develop metabolic dysfunction-associated steatohepatitis

Area of Science:

• Hepatology
• Metabolic disease research
• Drug development

Background:

• Monoacylglycerol acyltransferase 2 (MGAT2) plays a role in lipid metabolism.
• Inhibition of MGAT2 is a potential therapeutic strategy for fatty liver diseases.
• Humanized mouse models are essential for pre-clinical drug testing.

Purpose of the Study:

• To develop and characterize a humanized hMOGAT2 mouse model for MASH research.
• To evaluate the efficacy of hMOGAT2 inhibitors in a pre-clinical setting.
• To investigate the pathological mechanisms of MASH in the humanized model.

Main Methods:

• Generation of humanized hMOGAT2 (HuMgat2) mice.
• Induction of MASH using a steatotic diet.
• Histological and molecular analyses of liver tissues.
• RNASeq analysis to assess gene expression changes.
• Treatment with elafibranor to evaluate therapeutic effects.

Main Results:

• HuMgat2 mice fed a steatotic diet developed MASH with key pathological features including hepatocyte ballooning, inflammation, and fibrosis.
• Accumulation of Mallory-Denk bodies and evidence of impaired autophagy were observed.
• Metainflammation and apoptosis were present in the liver.
• Elafibranor treatment ameliorated several MASH phenotypes.
• RNASeq indicated altered bile acid metabolism and cholestasis.

Conclusions:

• The HuMgat2 mouse is a valuable pre-clinical model for studying MASH and testing hMOGAT2 inhibitors.
• This model facilitates the investigation of hMOGAT2's role in MASH pathogenesis.
• Findings support hMOGAT2 inhibition as a therapeutic avenue for MASH.